, providing the chance to discuss a paper published by Chaves et al. 4 , entitled "Public procurement of hepatitis C medicines in Brazil from 2005 to 2015".
Chaves et al. 4 assumed that by guaranteeing universal access to treatment, there would be room to lower the cost of acquisition of such expensive drugs. Despite, the economics principle of supply and demand applies to most of products, in health' care, efficacy, effectiveness and efficiency are also the landmarks for a feasible universal system. Improving access to DAA (Direct-Acting Antivirals) will happen by acquiring larger amounts of drugs at reduced costs and prescribing to earlier stages of HCV 3 . Whether the treatment achieves SVR (sustained virological remission) in a large group of patients as demonstrated in past clinical trials (RR 0.44, 95%CI 0.37~0.52) 3, 5 , the industry will be fully compensated. That is, the more effective DAA is, the higher will be the profits to patients and other stakeholders 1 . DAA efficacy has been demonstrated in controlled environments 5 . However, Real World Data (RWD) is needed to evaluate DAA in population scale 6 . Emerging countries, such as Brazil, work with the need to receive the maximum benefits of health care innovations in a shorter period of time than developed countries, due to the lower Gross Domestic Product (GDP) per capita. Thus, more mechanisms to guarantee risk sharing, correct use of DAA 7 , RWD analyses and better resource allocation are needed to overcome the higher initial investment.
Neither access to HCV nor lower costs preclude better health care. Brazil is on the way of P4P 2, 3 , by promoting HCV prevention, updating HCV guidelines, engaging professionals 2, 7 , industry 3 , health institutions 2 and RWD 6 analysts to work towards HCV SVR. That will be the key to truly improve viral liver diseases-induced morbimortality in Brazil.
